BlackRock Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$8.91M Sell
237,918
-274,177
-54% -$11.5M ﹤0.01% 953
2016
Q3
$34.7M Sell
512,095
-45,363
-8% -$3.2M 0.02% 670
2016
Q2
$30.9M Buy
557,458
+37,624
+7% +$2.37M 0.02% 681
2016
Q1
$32.6M Buy
519,834
+93,450
+22% +$6.21M 0.02% 680
2015
Q4
$40.1M Buy
426,384
+10,479
+3% +$972K 0.02% 633
2015
Q3
$33.4M Buy
415,905
+146,528
+54% +$16.3M 0.02% 665
2015
Q2
$32.3M Buy
269,377
+189,632
+238% +$22.7M 0.02% 698
2015
Q1
$8.33M Buy
79,745
+42,120
+112% +$4.27M ﹤0.01% 1004
2014
Q4
$3.65M Buy
37,625
+8,060
+27% +$747K ﹤0.01% 1223
2014
Q3
$2.31M Sell
29,565
-33,001
-53% -$2.13M ﹤0.01% 1363
2014
Q2
$3.95M Buy
62,566
+19,196
+44% +$1.14M ﹤0.01% 1204
2014
Q1
$2.91M Buy
43,370
+10,351
+31% +$801K ﹤0.01% 1349
2013
Q4
$2.12M Sell
33,019
-321,767
-91% -$19.2M ﹤0.01% 1490
2013
Q3
$22.7M Buy
354,786
+15,678
+5% +$781K 0.02% 734
2013
Q2
$10.5M Buy
+339,108
New +$9.02M 0.01% 848

Other funds holding ALNY